Scandion Oncology discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are world leaders in reverting the cancer’s resistance against treatment, thus making the treatment work better and longer thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 mio patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers. This gives us the potential to provide treatment to millions of people, who today don’t have effective treatment options.
We focus on clinical development of our most promising compounds to achieve proof of concept and confirmation hereof in pivotal trials. We fund our pipeline-investments through various sources, including capital raises, with the aim of ensuring maximum long term value creation for patients, investors, and society.
Globally, close to 10 mio patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers. This gives us the potential to provide treatment to millions of people, who today don’t have effective treatment options.
We focus on clinical development of our most promising compounds to achieve proof of concept and confirmation hereof in pivotal trials. We fund our pipeline-investments through various sources, including capital raises, with the aim of ensuring maximum long term value creation for patients, investors, and society.
Ticker:
SCOL
Exchange:
Nasdaq First North Growth Market
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Denmark
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
SCO-101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
